CVE:BTI Bioasis Technologies (BTI) Stock Price, News & Analysis C$0.0050 -0.01 (-50.00%) As of 03/18/2024 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Bioasis Technologies Stock (CVE:BTI) Get Bioasis Technologies alerts:Sign Up Key Stats Today's RangeC$0.01▼C$0.0150-Day RangeC$0.01▼C$0.0152-Week RangeC$0.01▼C$0.03Volume5,250 shsAverage Volume73,137 shsMarket CapitalizationC$397.05 thousandP/E RatioN/ADividend Yield40,400.00%Price TargetN/AConsensus RatingN/A Company Overview Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut. Read More Receive BTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioasis Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BTI Stock News HeadlinesRBT Rubicon Technologies, Inc.March 27, 2024 | seekingalpha.comBioasis Technologies: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (BTI)February 21, 2024 | theglobeandmail.comBillionaire Trader Warns: Get Out of StocksRay Dalio - who has made more money for clients than any hedge fund manager in history - is warning of a historic crisis for stocks that could keep portfolios in the red for 10 years. In the last three years alone, $31.5 trillion has been wiped from the market through annual crashes. More than 2,000 early adopters are already using a new TradeSmith tool designed to help protect and grow wealth regardless of what the market does next.July 2 at 1:00 AM | TradeSmith (Ad)Bioasis Technologies Inc BIOAFFebruary 16, 2024 | morningstar.comMBioasis Technologies: Top 10 Undervalued Biotechnology Industry Stocks (BTI)October 29, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc down on Friday (BTI)August 4, 2023 | theglobeandmail.comClosing Bell: Bioasis Technologies Inc flat on Tuesday (BTI)July 19, 2023 | theglobeandmail.comBioasis Provides Corporate Update and Announces Suspension of OperationsJune 20, 2023 | technews.tmcnet.comSee More Headlines BTI Stock Analysis - Frequently Asked Questions How have BTI shares performed this year? Bioasis Technologies' stock was trading at C$0.01 at the beginning of the year. Since then, BTI stock has increased by 0.0% and is now trading at C$0.01. How do I buy shares of Bioasis Technologies? Shares of BTI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Bioasis Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioasis Technologies investors own include Biora Therapeutics (BIOR), Bristol Myers Squibb (BMY), Novavax (NVAX), Ocugen (OCGN), Pfizer (PFE) and Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryTobacco Products Current SymbolCVE:BTI CIKN/A Webwww.bioasis.ca Phone+1-604-2957014FaxN/AEmployees52,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$2.88 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-80.58% Debt Debt-to-Equity Ratio27.88 Current Ratio0.11 Quick Ratio0.17 Sales & Book Value Annual SalesC$158.17 thousand Price / Sales2.51 Cash FlowC$0.00 per share Price / Cash Flow13.57 Book ValueC($0.03) per share Price / Book-0.17Miscellaneous Outstanding Shares79,410,000Free FloatN/AMarket CapC$397.05 thousand OptionableNot Optionable Beta0.45 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (CVE:BTI) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersWhat Happens to Your Assets If You Die Without a Will?Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores ...SmartAsset | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | SponsoredBillionaire Trader Warns: Get Out of StocksRay Dalio - who has made more money for clients than any hedge fund manager in history - is warning of a histo...TradeSmith | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredGold to $4,900—Here’s the Real PlayGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioasis Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioasis Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
